AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials-Reference-Cited by-同舟云学术

AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials

Published:2011-07 Issue:4 Volume:7 Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Vellas Bruno¹,Pesce Alain²,Robert Philippe H.³,Aisen Paul S.⁴,Ancoli‐Israel Sonia⁵,Andrieu Sandrine⁶,Cedarbaum Jesse⁷,Dubois Bruno⁸,Siemers Eric⁹,Spire Jean‐Paul¹⁰,Weiner Michael W.¹¹,May Thomas S.¹²

Affiliation:

1. Department of GeriatricsINSERM U558Toulouse University Hospital CenterToulouseFrance

2. Centre Hospitalier Princesse GraceMonacoMonaco

3. Centre MÉmoire CMRRNiceFrance

4. Department of NeurosciencesUniversity of CaliforniaSan DiegoCAUSA

5. Department of PsychiatryUniversity of California San DiegoSan DiegoCAUSA

6. Department of Epidemiology and Public HealthUniversity of ToulouseToulouseFrance

7. Elan Pharmaceuticals, Inc.South San FranciscoCAUSA

8. Centre des Maladies Cognitives et ComportementalesHôpital La SalpêtrièreParisFrance

9. Alzheimer's disease researchEli Lilly and CompanyIndianapolisINUSA

10. Department of NeurologyUniversity of ChicagoChicagoILUSA

11. Center for Imaging of Neurodegenerative DiseasesSan Francisco VA Medical CenterSan FranciscoCAUSA

12. Independent Medical WriterTorontoOntarioCanada

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2010.05.2020

Reference52 articles.

1. Alzheimer's Disease International.World Alzheimer report 2009. Available at:http://www.alz.co.uk/research/files/World%20Alzheimer%20Report.pdf. Accessed March 22 2010.

2. Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia

3. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

4. Memantine in Moderate-to-Severe Alzheimer's Disease

5. Janssen Pharmaceutica N.V. Belgium.Treatment of severe Alzheimer's disease: evaluation of efficacy and safety of galantamine hydrobromide in a controlled study. Available at:http://clinicaltrials.gov/ct2/show/NCT00216593. Accessed March 22 2010.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing Equitable Inclusion of Underrepresented Older Adults in Alzheimer’s Disease, Related Cognitive Disorders, and Aging-Related Research: A Scoping Review;The Gerontologist;2022-04-26

2. The Collaborative Approach for Asian Americans and Pacific Islanders Research and Education (CARE): A recruitment registry for Alzheimer's disease and related dementias, aging, and caregiver‐related research;Alzheimer's & Dementia;2022-04-14

3. Experiences of Participation in a Multimodal Preventive Trial MIND-ADMINI Among Persons with Prodromal Alzheimer’s Disease: A Qualitative Study;Journal of Multidisciplinary Healthcare;2022-01

4. Asian Americans and Pacific Islanders’ perspectives on participating in the CARE recruitment research registry for Alzheimer's disease and related dementias, aging, and caregiving research;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2021-01

5. Effectiveness of online education for recruitment to an Alzheimer's disease prevention clinical trial;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2020-01